DeepAI AI Chat
Log In Sign Up

Accurate collection of reasons for treatment discontinuation to better define estimands in clinical trials

by   Yongming Qu, et al.

Background: Reasons for treatment discontinuation are important not only to understand the benefit and risk profile of experimental treatments, but also to help choose appropriate strategies to handle intercurrent events in defining estimands and imputing missing values in data analyses. The current case report form (CRF) mixes the underlying reasons for treatment discontinuation and who makes the decision for treatment discontinuation, often resulting in an inaccurate collection of reasons for treatment discontinuation. Methods and results: We systematically reviewed and analyzed treatment discontinuation data from nine phase 2 and phase 3 studies for insulin peglispro. A total of 857 patients with treatment discontinuation were included in the analysis. Our review suggested that, due to the vague multiple-choice options for treatment discontinuation present in the CRF, different reasons were sometimes chosen for the same underlying reason for treatment discontinuation. Based on our review and analysis, we suggest an intermediate solution and a more systematic way to improve the current CRF for treatment discontinuations. Conclusion: This research provides insight and directions on how to optimize the CRF for recording treatment discontinuation. Further work needs to be done to build the learning into Clinical Data Interchange Standards Consortium standard.


Defining Estimands Using a Mix of Strategies to Handle Intercurrent Events in Clinical Trials

Randomized controlled trials (RCT) are the gold standard for evaluation ...

Estimands in Hematologic Oncology Trials

The estimand framework included in the addendum to the ICH E9 guideline ...

Decision curve analysis for personalized treatment choice between multiple options

Decision curve analysis can be used to determine whether a personalized ...

Transporting treatment effects with incomplete attributes

The simultaneous availability of experimental and observational data to ...

Revisiting ICH E9 (R1) during the COVID-19 pandemic

The current COVID-19 pandemic poses numerous challenges for ongoing clin...